Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

China Resources Pharmaceutical to Acquire 23.5% Stake in Lier Chemical to Advance Synthetic Biology Pipeline

Fineline Cube Jul 16, 2026
Company Deals

Braveheart Bio Files IPO Prospectus with Nasdaq for $1.8B Cardiac Myosin Inhibitor Asset

Fineline Cube Jul 16, 2026
Company Deals

WuXi Biologics Enters CDRMO Partnership with CANbridge Through 2028

Fineline Cube Jul 16, 2026
Company Deals

Innovent Biologics Secures $1.1B Global CD40L Antibody Deal with Spero Therapeutics

Fineline Cube Jul 15, 2026
Company Deals

Hansoh Pharmaceutical Secures $2.3B IL-23 Deal and Strategic Stake in Avere-NextCure Merger

Fineline Cube Jul 15, 2026
Policy / Regulatory

China’s CDE Releases Draft Guideline for Real-World Evidence-Based Pediatric Indication Expansion of Marketed Drugs

Fineline Cube Jul 16, 2026
Company Drug

Amoytop Biotech Secures NMPA Clinical Trial Approval for ACT201, Novel ASO Therapy for Chronic Hepatitis B

Fineline Cube Jul 16, 2026
Company Drug

Harbour BioMed and Kelun-Biotech Secure NMPA IND Approval for HBM7575/SKB575, Long-Acting Bispecific Antibody for Asthma

Fineline Cube Jul 16, 2026
Company

Novartis Launches Construction of First Radioligand Manufacturing Site in China

Fineline Cube Jul 3, 2024

Novartis AG (NYSE: NVS), the Swiss pharmaceutical giant, has initiated construction on its second manufacturing...

Company Drug

Eslicarbazepine Makes First Appearance in China at Sichuan University’s West China Lecheng Hospital

Fineline Cube Jul 3, 2024

Eslicarbazepine, a voltage-gated sodium channel blocker, co-developed by Bial-Portela, Eisai, and Sumitomo Pharma, was first...

Company Deals Medical Device

Jiangsu Vcare Pharma Partners with Geneseeq Technology to Develop Companion Diagnostic for NTRK Inhibitor

Fineline Cube Jul 3, 2024

Jiangsu Vcare PharmaTech Co., Ltd, a biopharmaceutical company based in China, has entered into a...

Company Drug

China’s Jiangsu Hengrui First to Market Generic Exparel in the US with FDA ANDA Approval

Fineline Cube Jul 3, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...

Company Drug

Shanghai Henlius Biotech Advances Serplulimab Phase III Trial for First-Line Metastatic Colorectal Cancer

Fineline Cube Jul 3, 2024

Shanghai Henlius Biotech Inc. (HKG: 2696), a biopharmaceutical company based in China, has announced that...

Company Drug

MabPharm’s Biosimilar Infliximab CMAB807 Receives Market Approval in Peru

Fineline Cube Jul 3, 2024

MabPharm Ltd (HKG: 2181), a biosimilar specialist in monoclonal antibody (mAb) based in Taizhou, has...

Company Drug

Legend Biotech’s Carvykti Shows Significant Overall Survival Improvement in Phase III CARTITUDE-4 Study

Fineline Cube Jul 3, 2024

Legend Biotech Corporation (NASDAQ: LEGN) has announced positive results from the CARTITUDE-4 study, a global,...

Company Drug

Lilly’s Kisunla Poised to Shake Up Alzheimer’s Treatment Market with FDA Approval

Fineline Cube Jul 3, 2024

Eli Lilly & Co. (NYSE: LLY) has announced that the U.S. Food and Drug Administration...

Company Drug

Johnson & Johnson’s Talvey Gets Green Light in South Korea for Multiple Myeloma

Fineline Cube Jul 3, 2024

Johnson & Johnson (J&J; NYSE: JNJ) has announced that its subsidiary Janssen Korea has received...

Company Policy / Regulatory

LEK Consulting’s Survey Reveals Biosecure Act’s Impact on Life Sciences Companies

Fineline Cube Jul 3, 2024

LEK Consulting, a UK/US firm, has published the results of a global survey aimed at...

Company Deals

Bristol-Myers Squibb Ends Collaboration with Eisai on Farletuzumab Eteribulin

Fineline Cube Jul 2, 2024

Bristol-Myers Squibb (BMS; NYSE: BMY), a prominent US pharmaceutical company, has decided to terminate its...

Company Drug

Eli Lilly & Co. Strikes Deal for Radionetics’ GPCR-Targeted Radiopharmaceuticals

Fineline Cube Jul 2, 2024

Eli Lilly & Co. (NYSE: LLY), a leading pharmaceutical company based in the US, has...

Company Drug

Boehringer Ingelheim Initiates Clinical Trial for Novel Anti-Obesity Drug

Fineline Cube Jul 2, 2024

Boehringer Ingelheim (BI), a German pharmaceutical company, has announced the commencement of clinical development for...

Company Drug

Tracon Pharmaceuticals Halts Development of Envafolimab After Clinical Trial Failure

Fineline Cube Jul 2, 2024

Tracon Pharmaceuticals (OTCMKTS: TCON), a US-based biopharmaceutical company, has decided to cease development of its...

Company Policy / Regulatory

US Forms ‘Bio-5’ Coalition with Global Powers to Reduce Reliance on Chinese APIs

Fineline Cube Jul 2, 2024

The White House announced last week a suite of new initiatives aimed at bolstering domestic...

Company Deals Medical Device

Cryofocus Medtech Partners with Boston Scientific for Respiratory Products Distribution in China

Fineline Cube Jul 2, 2024

Cryofocus Medtech (Shanghai) Co., Ltd. (HKG: 6922), a Shanghai-based specialist in cryoablation treatment, has announced...

Company Deals

PW Medtech Group Ltd Plans Independent Listing of Rekind Medtec on NEEQ to Boost Growth

Fineline Cube Jul 2, 2024

PW Medtech Group Ltd (HKG: 1358), a prominent medical device manufacturer based in China, is...

Company Drug

Innovent Biologics Presents Positive Phase I Results for IBI343 at ESMO GI Congress 2024

Fineline Cube Jul 2, 2024

Innovent Biologics Inc. (HKG: 1801), a leading biopharmaceutical company based in China, has announced the...

Company Medical Device

Ningbo-Based Jenscare Scientific Announces Successful Follow-up Data for Transjugular Tricuspid Valve Device

Fineline Cube Jul 2, 2024

Jenscare Scientific Co., Ltd (HKG: 9877), a leading manufacturer of structural heart disease devices headquartered...

Company Drug

Yantai Dongcheng Pharmaceutical’s 177LuLNC1011 Gets FDA Green Light for Prostate Cancer Clinical Trial

Fineline Cube Jul 2, 2024

Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675), a pharmaceutical company based in China, has...

Posts pagination

1 … 366 367 368 … 696

Recent updates

  • Amoytop Biotech Secures NMPA Clinical Trial Approval for ACT201, Novel ASO Therapy for Chronic Hepatitis B
  • Boehringer Ingelheim Reports 16.2% H1 2026 Sales Growth Driven by JARDIANCE and New Oncology Launches
  • China Resources Pharmaceutical to Acquire 23.5% Stake in Lier Chemical to Advance Synthetic Biology Pipeline
  • Harbour BioMed and Kelun-Biotech Secure NMPA IND Approval for HBM7575/SKB575, Long-Acting Bispecific Antibody for Asthma
  • Hengrui Pharmaceuticals Secures Dual NMPA Approvals for HRS-8797 Atopic Dermatitis Drug and HRS-8829 Stroke Therapy
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Amoytop Biotech Secures NMPA Clinical Trial Approval for ACT201, Novel ASO Therapy for Chronic Hepatitis B

Company

Boehringer Ingelheim Reports 16.2% H1 2026 Sales Growth Driven by JARDIANCE and New Oncology Launches

Company Deals

China Resources Pharmaceutical to Acquire 23.5% Stake in Lier Chemical to Advance Synthetic Biology Pipeline

Company Drug

Harbour BioMed and Kelun-Biotech Secure NMPA IND Approval for HBM7575/SKB575, Long-Acting Bispecific Antibody for Asthma

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.